Effective, ongoing, and safe therapies are essential in modern medicine, and they primarily depend on precise medication distribution and action. The creation of drug delivery devices with better pharmacokinetic properties and increased transport to target tissues makes progress in this field easier. A number of FDA-approved therapeutic nanoparticles, such as Abraxane for metastatic breast cancer and non-small cell lung carcinoma, Optison for ultrasound imaging, and Nanocoll for SPECT diagnostics in sentinel node location, highlight human serum albumin as a promising carrier. Significant progress is expected in the treatment of soft tissue tumors, as LadRx is working to get FDA approval for Aldoxorubicin. Theranostics, which combines medications with tumor-localizing factors to efficiently target cancer cells and initiate cytotoxicity at the diseased location, offers a promising future for oncology. In addition to discussing synthesis and surface modification methods for improved targeted delivery, this paper highlights current advancements in albumin-based nanoparticles with an emphasis on drug administration, targeting, and imaging. Innovative multimodal theranostic approaches that take advantage of albumin's characteristics to improve cancer treatments are described in the conclusion.
Yuvalakshmi E.1*, Ashokkumar V. M.2, Priyan R.3, Hariharan G.4, Darnia Vasanthi A.5, Dr. Sathish A.6 (Sat,) studied this question.